Sphingosine‐1‐phosphate antibodies as potential agents in the treatment of cancer and age‐related macular degeneration

• Published in: British journal of pharmacology Vol. 162; no. 6; pp. 1225 - 1238
• Main Author: Sabbadini, Roger A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2011; Nature Publishing Group; Blackwell Science Inc
• Subjects: age‐related macular degeneration; Antibodies, Monoclonal - therapeutic use; antibody therapeutics; Biological and medical sciences; cancer; choroidal neovascularization; Drug Discovery; Humans; Lysophospholipids - immunology; Lysophospholipids - metabolism; Macular degeneration; Medical sciences; Molecular Targeted Therapy; Neoplasms - metabolism; Neoplasms - therapy; ocular disease; Ophthalmology; Pharmacology. Drug treatments; Receptors, Lysosphingolipid - metabolism; retinal pigmented epithelial cells; Retinopathies; Reviews; S1P; Signal Transduction - drug effects; Sphingosine - analogs & derivatives; Sphingosine - immunology; Sphingosine - metabolism; Sphingosine‐1‐phosphate; wet AMD; Wet Macular Degeneration - therapy; antibody therapeutics; Retinopathy; Choroidal neovascularization; Antibody; Retina; Malignant tumor; ocular disease; wet AMD; Eye; Visual system; Eye disease; Treatment; S1P; Sphingosine-1-phosphate; Pigments; Epithelial cell; Age related macular degeneration; retinal pigmented epithelial cells; Retinal; age-related macular degeneration; Cancer
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.2010.01118.x

Sphingosine‐1‐phosphate (S1P) is a pleiotropic bioactive lipid thought to be dysregulated in a variety of disease conditions. In this review, we discuss the roles of S1P in cancer and in wet age‐related macular degeneration. We also explore potential treatment strategies for these disorders, including the utility of anti‐S1P antibodies acting as molecular sponges to neutralize dysregulated S1P in relevant tissues.